CalciMedica
505 Coast Boulevard South
Suite 209
La Jolla
California
92037
United States
Tel: 858-952-5500
Fax: 858-952-5490
Website: http://www.calcimedica.com/
Email: info@calcimedica.com
71 articles about CalciMedica
-
CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia
1/20/2022
CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the initiation of CARDEA-Plus, a Phase 2b clinical trial being conducted in the United States and Canada, that may serve as a lead-in to its Phase 3 development program of Auxora™ in patients with critical COVID-19 pneumonia.
-
CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial
9/14/2021
CalciMedica Inc. ("CalciMedica" or the "Company"), the CRAC channel company, today announced the results from CARDEA, a Phase 2 trial of its lead drug candidate Auxora™ in patients with severe COVID-19 pneumonia.
-
CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways
9/9/2021
CalciMedica Inc. ("CalciMedica" or the "Company"), the CRAC channel company, today announced the publication of preclinical data validating calcium release-activated calcium (CRAC) channels, P2Y2 receptors, and P2X receptors as potential drug targets for diseases of the airways in the peer-reviewed Journal of Immunology.
-
CalciMedica Publishes Positive Data from Phase 2a Study of Auxora™ in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study
6/2/2021
CalciMedica Inc. ("CalciMedica" or the "Company), a clinical-stage biotechnology platform company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the publication of results from the Company's completed randomized, open-label, dose-response Phase 2a study in the peer-reviewed journal Pancreas
-
If these companies are any indication, it appears that the biopharma industry will be a hybrid of virtual and physical workforces, and with this comes a whole new set of risks.
-
BioSpace Movers & Shakers, March 19
3/19/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
CalciMedica Announces $21 Million Series D Financing
3/11/2021
CalciMedica Inc. (“CalciMedica” or the “Company”), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced it has secured a $21 million Series D financing led by Quark Venture LP and GHS Fund (Quark Venture LP and GF Securities) and joined by previous investors,
-
It was a busy week for clinical trial updates. Here’s a look.
-
CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress
2/2/2021
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the presentation of new clinical data from the open-label, placebo-controlled trial of Auxora™ in patients with severe COVID-19 pneumonia.
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
Vir and GSK Dose First Patient in COVID-19 Monoclonal Antibody Study and Other Pandemic Updates
12/18/2020
Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study assessing the monoclonal antibody VIR-7831 as a potential treatment of hospitalized adults diagnosed with COVID-19. -
As we eagerly look ahead to 2021, BioSpace spoke to four biotechs hoping to seize this opportunity in the first wave of COVID-19 vaccines and therapies – or make an impact in the second.
-
CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
12/17/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the treatment of severe acute and chronic inflammatory diseases, today announced that the trial evaluating Auxora™ in patients with severe COVID-19 pneumonia has received a recommendation to continue
-
CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke
11/13/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced the publication of preclinical data demonstrating a pathological role for CRAC channel-mediated microglial calcium activity in ischemic brain injury in the peer-reviewed journal Stroke.
-
CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer
11/5/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe acute and chronic inflammatory diseases, today announced it has appointed Daniel Geffken as the interim chief financial officer.
-
CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia
8/18/2020
Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of care alone Clinical trial to enroll up to 400 patients at sites across the U.S., including California, Texas and Louisiana, is being initiated this week
-
CalciMedica and EpiPharma Enter into Research Collaboration to Discover and Develop CRAC Channel Inhibitor Therapies
7/21/2020
Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline LA JOLLA, Calif. and SZEGED, Hungary and BUDAPEST, Hungary, July 21, 2020 (GLOBE NEWSWIRE) -- CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, and EpiPharma, a
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
-
CalciMedica Announces Data Showing Auxora™ Substantially Improved Outcomes in Patients with Severe COVID-19 Pneumonia
7/16/2020
CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced data from a randomized, controlled, open-label clinical study showing substantially improved outcomes with Auxora™ (formerly called CM4620-IE) as a treatment for severe COVID-19 pneumonia.
-
BioSpace Movers & Shakers, June 5
6/5/2020
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.